financetom
Business
financetom
/
Business
/
US CFPB scraps Citibank discrimination case three years early
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US CFPB scraps Citibank discrimination case three years early
Oct 16, 2025 2:56 PM

WASHINGTON (Reuters) -The top U.S. consumer finance watchdog agency on Thursday terminated a 2023 enforcement case against Citigroup's ( C/PN ) lending arm Citibank that had penalized the banking giant for alleged discrimination against Armenian Americans in California.

Citibank in 2023 agreed to pay nearly $26 million in fines and consumer redress to resolve allegations that it had intentionally discriminated against credit card applicants based on their last names and then illegally fabricated records to cover this up.

At the time, Citigroup ( C/PN ) apologized, saying a "small number" of employees had circumvented protocols when trying to thwart an Armenian fraud ring and that those involved had been disciplined.

In an order posted Thursday to the CFPB's website, acting Director Russell Vought said the CFPB had terminated the consent order, noting that the bank had paid the settlement costs and taken steps to prevent future violations.

Representatives for the CFPB and Citigroup ( C/PN ) declined to comment. Vought, who is also President Donald Trump's budget director and has overseen efforts to slash the federal workforce, said Wednesday he expected to shut the CFPB down within months.

The original 2023 consent order was due to remain in force for another three years and contained provisions requiring the bank to supply the CFPB with compliance records on request and make employees and others available to investigators if necessary.

Since Trump took control of the CFPB in February, the agency has sought to undo several already-resolved enforcement actions, including cases against Toyota Motor Credit, Bank of America, Apple and US Bank. It has also dropped pending cases en masse.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Carlyle-backed StandardAero targets $7.7 bln valuation in upsized IPO
Carlyle-backed StandardAero targets $7.7 bln valuation in upsized IPO
Sep 27, 2024
Sept 27 (Reuters) - Carlyle-backed aviation services provider StandardAero is targeting a valuation of up to $7.69 billion in an upsized initial public offering, underscoring the strong investor appetite for profitable companies with scale. The company is now targeting a sale of 60 million shares priced between $20 and $23 each, to fetch $1.38 billion, it said on Friday. It...
US Foods Unit to Offer $500 Million Senior Notes Due 2033
US Foods Unit to Offer $500 Million Senior Notes Due 2033
Sep 27, 2024
08:16 AM EDT, 09/27/2024 (MT Newswires) -- US Foods Holding ( USFD ) said Friday that its US Foods Inc. unit intends to offer $500 million of senior unsecured notes due 2033. The notes will be sold in a private offering, and the net proceeds are expected to be used to partially repay amounts outstanding under the unit's term loan...
Dropbox Insider Sold Shares Worth $3,655,622, According to a Recent SEC Filing
Dropbox Insider Sold Shares Worth $3,655,622, According to a Recent SEC Filing
Sep 27, 2024
09:25 AM EDT, 09/27/2024 (MT Newswires) -- Andrew Houston, 10% Owner, Director, Chief Executive Officer, around September 24, 2024, sold 146,094 shares in Dropbox ( DBX ) for $3,655,622. Following the Form 4 filing with the SEC, Houston has control over a total of 9,427,838 shares of the company, with 8,266,666 shares held directly and 1,161,172 shares controlled indirectly. SEC...
Johnson & Johnson Says Results From Blood Cancer Drug Study Support Further Evaluation
Johnson & Johnson Says Results From Blood Cancer Drug Study Support Further Evaluation
Sep 27, 2024
08:41 AM EDT, 09/27/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that an investigational phase 1 study evaluating the combination of Talvey with Darzalex Faspro and pomalidomide in patients with relapsed or refractory multiple myeloma showed an overall response rate of 82%. The company said the data supports continued investigation of the drug combination. The study...
Copyright 2023-2026 - www.financetom.com All Rights Reserved